3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Lymphoma
142
Leukemia
111
Leukemia, Myeloid, Acute
100
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Lymphoma, Non-Hodgkin
91
Multiple Myeloma
88
Lymphoma, Large B-Cell, Diffuse
80
Myelodysplastic Syndromes
74
Lymphoma, Follicular
73
Lymphoma, Mantle-Cell
72
Leukemia, Lymphocytic, Chronic, B-Cell
69
Burkitt Lymphoma
67
Hodgkin Disease
66
Lymphoma, Large-Cell, Immunoblastic
60
Lymphoma, B-Cell, Marginal Zone
49
Breast Neoplasms
48
Neoplasms, Plasma Cell
39
Leukemia, Myeloid, Accelerated Phase
34
Leukemia, Myeloid, Chronic-Phase
33
Recurrence
32
Myeloproliferative Disorders
32
Ovarian Neoplasms
31
Congenital Abnormalities
30
Blast Crisis
30
Sarcoma
28
Dendritic Cell Sarcoma, Interdigitating
28
Central Nervous System Neoplasms
28
Leukemia, Myelomonocytic, Chronic
27
Neuroblastoma
25
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
21
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
Filgrastim
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts